No significant difference for improvement of erosive hand OA pain between adalimumab and placebo
A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis - the HUMOR trialOsteoarthritis Cartilage. 2018 Jul;26(7):880-887. doi: 10.1016/j.joca.2018.02.899
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
43 patients with erosive hand osteoarthritis were included in a crossover, randomized design to evaluate the efficacy of adalimumab as a treatment option. Patients were randomized to the order in which they received intervention with either adalimumab or placebo for 12 weeks. There was an 8-week washout period between treatment phases. Improvement in patient-reported pain, stiffness, and function ...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE